Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NTRBW) delivers innovative transdermal solutions addressing critical pharmaceutical safety challenges through its proprietary AVERSA® technology. This dedicated news hub provides investors and industry stakeholders with essential updates about regulatory progress, product development milestones, and strategic partnerships.
Access real-time announcements covering clinical trial developments, intellectual property expansions, manufacturing agreements, and consumer product launches. Our curated feed includes earnings reports, FDA submission updates, and analysis of technologies combating opioid misuse through abuse-deterrent systems.
Key focus areas include advancements in transdermal drug delivery systems, international patent grants, and collaborations with industry leaders like Kindeva Drug Delivery. Stay informed about Nutriband's progress in integrating Bitrex®-based safety mechanisms across therapeutic applications while maintaining compliance with global regulatory standards.
Bookmark this page for verified updates about Nutriband's mission to enhance medication safety through cutting-edge transdermal innovations. Monitor critical developments in pharmaceutical abuse prevention and topical delivery systems from a single authoritative source.
Nutriband Inc. (NASDAQ:NTRB) reported significant growth in its Q2 2022 financial results, achieving record quarterly revenue of $0.5 million, a 113% increase year-over-year. Over six months, revenue rose 44%. The company received a favorable court ruling enabling the cancellation of 1.2 million shares, representing 15% of outstanding shares at the time. Nutriband continues to expand its AVERSA™ intellectual property, now protected in 45 countries. However, net loss increased to $1.0 million from $0.5 million year-over-year.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the effective date of a 7:6 forward stock split that took place on August 12, 2022, with a record date of August 15, 2022. Each holder of 6 shares of common stock received 7 shares, with no change to the per-share par value. The stock split will not affect stockholders' equity percentages. Additionally, the exercise price of outstanding warrants will be adjusted to $6.43 per share, corresponding to the stock split ratio. Book-entry holders do not need to take action, while those seeking stock certificates will receive further instructions.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the receipt of a Notice of Allowance for its patent application from the Canadian Intellectual Property Office. This patent is crucial for the company's AVERSA™ transdermal abuse deterrent technology, enhancing intellectual property protection across North America.
The AVERSA™ technology aims to reduce drug misuse and abuse while ensuring accessibility for patients in need. The lead product, AVERSA™ Fentanyl, is projected to achieve peak annual sales of $80M - $200M. Nutriband's patent portfolio spans multiple countries, bolstering its market position.
Nutriband Inc. (NTRB, NTRBW) announced a 7:6 forward stock split effective at 12:01 AM on August 15, 2022. Shareholders will receive seven shares for every six shares held, maintaining the par value. CEO Gareth Sheridan emphasized the company's commitment to creating shareholder value following recent milestones. Nutriband is focused on developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing its AVERSA technology. The company acknowledges various risks involved in its development and regulatory processes.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced a favorable Final Judgment allowing the cancellation of 1.2 million shares, approximately 15% of its outstanding shares, previously issued for an acquisition now rescinded. This cancellation, expected to be processed within one business day, will reduce Nutriband's total outstanding shares to 6.6 million. The company is focused on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing the AVERSA technology.
Nutriband Inc. (NASDAQ:NTRB, NASDAQ:NTRBW) has announced the opening of a new branch in Quito, Ecuador, aimed at expanding its product offerings in the region through product registration and contract services. CEO Gareth Sheridan emphasized this move as a significant step towards enhancing revenue opportunities and building relationships. The company specializes in developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing AVERSA® technology. This expansion marks a strategic initiative to penetrate the South American market.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) is set to be featured in an interview on Bloomberg TV on July 23 at 7 p.m. ET. CEO Gareth Sheridan will discuss revenue growth, partnerships, and the company's role in addressing the opioid crisis with its innovative AVERSA technology. The company specializes in transdermal pharmaceutical products, primarily an abuse-deterrent fentanyl patch. This broadcast reaches approximately 73 million households in the U.S., enhancing visibility for Nutriband's initiatives and offerings.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a favorable court verdict regarding its 2017 acquisition of Advanced Health Brands, allowing the recovery of 4.8 million shares that had been issued as part of the deal. After a reverse split in 2018, this recovery translates to approximately 1.2 million shares, or 15% of the company’s total outstanding shares. This successful legal outcome is expected to reduce Nutriband's total outstanding shares, positively impacting shareholder value.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) endorses the updated CDC guidelines for opioid prescription, advocating for comprehensive pain management that includes responsible opioid use. The draft guidelines have received positive feedback, suggesting a need to ease restrictions for patients suffering from severe pain. Nutriband's AVERSA™ technology aims to prevent opioid abuse through its unique transdermal patches. This could lead to significant sales, estimated at $80M - $200M within five years. The company holds broad patent protections for this technology globally.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that CEO Gareth Sheridan will be featured on The RedChip Money Report on Bloomberg TV, airing on May 28 at 7 p.m. ET. This program, focused on small-cap investing, reaches approximately 73 million homes in the U.S. Nutriband is developing transdermal pharmaceutical products, including an abuse deterrent fentanyl patch utilizing AVERSA™ technology. The company aims to prevent misuse and accidental exposure to drugs with abuse potential. For more information, visit www.nutriband.com.
FAQ
What is the current stock price of Nutriband (NTRBW)?
